In melanomas, the administration of doxorubicin can trigger caspase-3-driven pyroptosis via GSDME, and the antitumor efficacy is enhanced when the elongation factor-2 kinase (eEF-2K) is inhibited (75, 93). Here, EEF2K is linked to melanoma.